ArticleAIDS and behavior2026
High Burden of Sexually Transmitted Infections Among Pre-exposure Prophylaxis (PrEP) Users: Testing and Prevention Needs.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-exposure prophylaxis (PrEP) effectively prevents HIV acquisition but does not protect against other sexually transmitted infections (STIs). Rising STI rates among PrEP users have raised concerns about risk compensation and highlight the need for integrated sexual health strategies. We assessed the prevalence, anatomical distribution, and behavioural determinants of STIs among PrEP users in Spain. This retrospective observational study included 724 individuals receiving daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) at a tertiary hospital in Madrid between March and October 2023, with one year of follow-up. Sociodemographic, behavioural, and microbiological data were obtained from medical records and electronic questionnaires. Routine quarterly PCR screening for Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis was performed using anal, pharyngeal, and urine samples. During follow-up, 476 participants (65.7%) were diagnosed with at least one STI, accounting for 968 infectious episodes and 1271 pathogen detections. Neisseria gonorrhoeae (35.3%) and Chlamydia trachomatis (30.3%) accounted for two-thirds of episodes, followed by Mycoplasma genitalium (17.4%) and Treponema pallidum (9%). Most positive samples were anal (566; 55.1%), followed by pharyngeal (271; 26.4%) and urinary (190; 18.5%) samples. One participant acquired HIV (0.1%). Younger age, a higher number of sexual partners, and chemsex practices were independently associated with STI diagnosis. The high burden of bacterial STIs, particularly at anal sites, supports systematic multisite testing, adherence support, behavioural interventions, and consideration of additional prevention strategies, including doxycycline post-exposure prophylaxis and future gonococcal vaccines, within PrEP programmes.
Indexed as
Identifiers
42501237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.